Which of the following are recognized extraglandular manifestations of Sjögren’s syndrome: thrombocytopenia, chronic myelogenous leukemia (CML), bronchiectasis, or ulcerative colitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Extraglandular Manifestations of Sjögren's Syndrome

Among the options listed, thrombocytopenia and bronchiectasis are recognized extraglandular manifestations of Sjögren's syndrome, while CML and ulcerative colitis are not established associations.

Recognized Extraglandular Manifestations

a) Thrombocytopenia - YES

Thrombocytopenia is a well-documented hematologic extraglandular manifestation of Sjögren's syndrome. The 2021 Chest consensus guidelines specifically list thrombocytopenia among the known risk factors for lymphoproliferative complications in Sjögren's patients 1. Multiple case reports confirm that immune-mediated cytopenias, including thrombocytopenia, can present as clinically significant extraglandular manifestations of primary Sjögren's syndrome 2, 3, 4.

  • Clinical presentation: Can occur with or without sicca symptoms
  • Mechanism: Immune-mediated platelet destruction
  • Treatment response: Typically responds well to corticosteroid therapy 2
  • Diagnostic consideration: Sjögren's syndrome should be actively sought in patients with apparently "idiopathic" thrombocytopenia through directed history, Schirmer test, and autoantibody screening 3

c) Bronchiectasis - YES

Bronchiectasis is a clearly established pulmonary manifestation of Sjögren's syndrome. The 2021 Chest consensus guidelines provide strong recommendations (LOW evidence, STRONG recommendation) for managing clinically relevant bronchiectasis in Sjögren's patients 1.

  • Prevalence: Upper and lower airway disease is reported in association with Sjögren's 1
  • Radiographic definition: Atypical dilation of airways larger than the accompanying bronchial artery, or visible to 1 cm of the costal pleural margin 1
  • Clinical context: Part of the spectrum of pulmonary complications including xerotrachea, bronchiolitis, obstructive lung disease, and interstitial lung disease 5, 6
  • Management: Treat similarly to primary or secondary bronchiectasis of other etiologies, including mucolytic agents, nebulized saline, airway clearance techniques, and chronic macrolides (in absence of non-tuberculous mycobacterium) 1

Non-Recognized Associations

b) CML (Chronic Myelogenous Leukemia) - NO

CML is not an established extraglandular manifestation of Sjögren's syndrome. While Sjögren's patients have increased risk for lymphoproliferative disorders (particularly B-cell lymphomas, especially MALT lymphoma), this represents lymphoid rather than myeloid malignancy 1. The lymphoma risk in Sjögren's ranges from 5-18%, but these are predominantly B-cell non-Hodgkin lymphomas, not myeloid leukemias.

d) Ulcerative Colitis - NO

Ulcerative colitis is not recognized as an extraglandular manifestation of Sjögren's syndrome. The provided evidence includes comprehensive reviews of extraglandular manifestations 5, 6, 7, 8, and none mention inflammatory bowel disease as an associated feature. The 2020 EULAR recommendations 9 and multiple systematic reviews of extraglandular manifestations do not list gastrointestinal inflammatory conditions like ulcerative colitis among the systemic features of Sjögren's syndrome.

Clinical Pearls

Common pitfall: Failing to recognize that Sjögren's syndrome can present with extraglandular manifestations (including thrombocytopenia or pulmonary disease) in the absence of sicca symptoms 3. Maintain high clinical suspicion and actively screen with autoantibodies (anti-SSA/Ro, anti-SSB/La), Schirmer test, and directed history when encountering unexplained cytopenias or pulmonary disease.

Answer: a) and c) are correct

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.